CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 496 enrolled
Drug / intervention
Reveal LINQ™ Insertable Cardiac Monitordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02700945
NCT02700945N/ACompleted
CompareCT.gov

Stroke AF - Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin

Medtronic Cardiac Rhythm and Heart Failure·interventional·Posted Mar 7, 2016·Updated May 26, 2023

In Brief

A clinical study evaluating Reveal LINQ™ Insertable Cardiac Monitor for Stroke, Acute. Completed, enrolled 496 participants across 35 sites.

Detailed Summary

The purpose of the Stroke AF study is to compare the incidence of atrial fibrillation (AF) through 12 months between continuous cardiac rhythm monitoring with the Reveal LINQ™ Insertable Cardiac Monitor (ICM) (continuous monitoring arm) and standard of care (SoC) medical treatment (control arm) in subjects with a recent ischemic stroke of presumed known origin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Acute
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 7, 2016
Enrollment StartMar 1, 2016
Primary CompletionAug 3, 2020
Study CompletionJul 28, 2022
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.3 years ago

Interventions

Reveal LINQ™ Insertable Cardiac Monitordevice

The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.